Did you know that there’s a version of semaglutide that costs half as much as Wegovy and uses the same active ingredient? The same goes for tirzepatide and Zepbound. They’re called compounded GLP-1 medications (compounded semaglutide and compounded tirzepatide), and they’ve become one of the most common ways you can access GLP-1 treatment without paying […]
By Astra Editorial Team
Medically reviewed by Dr. Keanna Tofiga on 2026-03-27
Published:
Updated:
Compounded GLP-1 medications contain the same active ingredients as Wegovy and Zepbound, prepared by licensed pharmacies at $150-$400/month versus $299-$449+ for brand-name.
They require a prescription but are not FDA-approved as finished products. Compounding remains legal in 2026 through 503A pharmacies under stricter conditions than during the shortage.
Did you know that there’s a version of semaglutide that costs half as much as Wegovy and uses the same active ingredient? The same goes for tirzepatide and Zepbound. They’re called compounded GLP-1 medications (compounded semaglutide and compounded tirzepatide), and they’ve become one of the most common ways you can access GLP-1 treatment without paying brand-name prices.
In this article, I’ll cover the basics about compounded GLP-1 medications: what they are, how they differ from brand-name GLP-1s, the current regulatory picture, and what to look for in a telehealth platform when purchasing compounded GLP-1s (whether that’s through us or someone else).
If you’re still getting up to speed on GLP-1 medications in general, start with our complete GLP-1 guide.
Compounded GLP-1 medications are versions of drugs prepared by licensed compounding pharmacies based on an individual patient’s prescription, rather than manufactured by the original drug companies (Novo Nordisk for Wegovy and Eli Lilly for Zepbound).
The FDA defines compounding as a practice in which a pharmacist or physician combines, mixes, or alters ingredients to create a medication tailored to an individual patient. It’s regulated under Section 503A of the Federal Food, Drug, and Cosmetic Act for traditional pharmacies and Section 503B for outsourcing facilities.
So why did compounding become such a big part of the GLP-1 conversation? Two reasons: first, brand-name GLP-1s entered the market at a hefty price of over $1,000 per month.
Second, they ran out. When Wegovy and Ozempic landed on the FDA drug shortage list in 2022, followed by Mounjaro later that year and Zepbound after its 2023 approval, the FDA authorized compounding pharmacies to step in and produce compounded semaglutide and compounded tirzepatide to meet patient demand.
That, combined with significantly lower prices, is how compounded GLP-1s became a mainstream option. Indeed, for many patients, compounded GLP-1s were the only way to start treatment at all.
No. A generic drug is made by a different manufacturer but goes through its own FDA approval process. So, the FDA reviews it, confirms it works the same way as the brand-name version, and approves it for sale. When a generic drug exists, you can buy it at any pharmacy just like the original. Take generic Advil, for instance. It’s FDA-approved ibuprofen made by someone other than the original company.
A compounded drug is different. A licensed pharmacist prepares it for a specific patient based on that patient’s prescription. The active ingredient in the compounded drug may be the same one that’s in the FDA-approved brand-name drug, but the vial you receive has not gone through FDA review as a finished medication.
There are no generic versions of Wegovy or Zepbound available yet. So when you hear people talk about “cheaper semaglutide” or “cheaper tirzepatide,” they’re almost always talking about compounded GLP-1s, not generic.
| Compounded GLP-1s | Brand-Name GLP-1s | |
|---|---|---|
| Active Ingredient | Same (semaglutide or tirzepatide) | Same (semaglutide or tirzepatide) |
| Active Ingredient Evaluated by the FDA? | Yes | Yes |
| FDA-Approved as Finished Product? | No | Yes |
| Manufacturing | Licensed compounding pharmacies (503A/503B), following USP standards | Large-scale pharmaceutical facilities (Novo Nordisk, Eli Lilly) |
| Delivery Format | Vials (you draw the dose with a syringe) | Pre-filled injection pens |
| Cost (Self-Pay/Month) | Semaglutide: $150-$300 Tirzepatide: $200-$400 | Wegovy: $349+ Zepbound: $299-$449 |
| Requires Prescription? | Yes | Yes |
The active ingredient in a compounded GLP-1 medication is the same as that of a brand-name GLP-1. Compounded semaglutide uses the same molecule as Wegovy and Ozempic. Compounded tirzepatide uses the same molecule as Zepbound and Mounjaro. How the drug works in your body doesn’t change based on who prepared it.
The FDA approval status is different. The active ingredients (semaglutide and tirzepatide) in compounded GLP-1s have been evaluated by the FDA. They are the same active ingredients in the brand-name drugs.
But the final compounded product you receive (the vial itself) has not been evaluated nor approved by the FDA, whereas brand-name GLP-1s undergo the FDA approval process.
The manufacturing process is different. Novo Nordisk and Eli Lilly produce GLP-1s in large-scale pharmaceutical facilities with standardized processes. Compounded GLP-1s are prepared by individual pharmacies following United States Pharmacopeia (USP) standards. Quality can vary between pharmacies, which is why the pharmacy you use matters as much as the drug itself.
The FDA has raised concerns that some compounders are using semaglutide sodium or semaglutide acetate instead of semaglutide base.
The approved drugs (Wegovy, Ozempic) use semaglutide base. The FDA considers the salt forms to be different active ingredients, which puts products made with them on shaky regulatory ground.
If you’re evaluating a compounded provider, ask which form of semaglutide they use. If they can’t answer clearly, that’s a red flag.
The delivery format is different. Brand-name GLP-1s come in pre-filled injection pens. You click and inject. Compounded versions typically come in vials, and you draw the dose into a syringe yourself. It’s not difficult, but it is a different experience.
The cost is significantly different. As we covered in our GLP-1 cost breakdown, brand-name Wegovy runs about $349/month at self-pay maintenance doses, and Zepbound ranges from $299 to $449. Compounded semaglutide typically costs $150 to $300/month, and compounded tirzepatide runs $200 to $400/month.
If you’re paying out of pocket (and you’re not alone given that fewer than one in four employer plans cover GLP-1s for weight loss), compounded options are often the difference between being able to afford treatment and not, especially if you need to stay on it for the long term.
If you’re trying to decide between semaglutide and tirzepatide, our full comparison covers efficacy, side effects, heart data, and cost-per-result.
Yes, with conditions. The rules are stricter than they were during the shortage, but the pathway for patient-specific compounding through licensed 503A pharmacies remains intact.
Here’s what happened.
The FDA adds semaglutide injection products (Ozempic, Wegovy) to the drug shortage list. Under federal law, compounding pharmacies can produce copies of drugs that are in shortage. Compounded semaglutide becomes widely available.
Tirzepatide (Mounjaro, Zepbound) is also added to the shortage list. Compounded tirzepatide follows.
The FDA resolves the tirzepatide shortage. Enforcement discretion periods begin winding down for compounders.
The FDA removes semaglutide from the shortage list. The same enforcement discretion periods apply: 503A pharmacies get 60 days, 503B outsourcing facilities get 90 days. Those windows have since closed.
The FDA states its intent to take action against non-FDA-approved GLP-1 drugs. A subsequent clarification specifies that the agency is not banning all compounding. Instead, it’s targeting compounding without documented medical necessity, unlicensed operations, misleading marketing, and poor ingredient sourcing.
As things stand now, the broad compounding authority that existed during the shortage is over. But 503A pharmacies can still legally compound semaglutide and tirzepatide for patient-specific prescriptions when a licensed provider determines the patient’s needs cannot be met by the commercially available product.
The Outsourcing Facilities Association, a trade group representing compounding facilities, has sued the FDA over the shortage determination, arguing that supply still isn’t meeting demand. That lawsuit is ongoing.
Compounded GLP-1 medications are not for everyone. But for a specific group of people, they do fill a gap that brand-name options like Wegovy and Zepbound do not.
You might be a good candidate for compounded GLP-1s if:
You’re probably better served by a brand-name product if your insurance covers it, if you can access manufacturer savings programs that bring your cost down, or if you prefer the convenience of a pre-filled pen and the assurance of FDA approval on the finished product.
If you go through a legitimate compounded GLP-1 provider, the process is more straightforward than most expect.
Ask these questions before you commit to a compounded GLP-1 provider:
Can they name it? A legitimate provider will tell you exactly which pharmacy prepares your medication.
Reputable pharmacies will reference USP General Chapter standards for sterile preparations.
If all you had to do was fill out a form and enter your credit card, that’s not a medical evaluation. A real provider reviews your health history, asks about contraindications, and has a licensed prescriber make the decision.
Dose adjustments, side effect management, and check-ins are part of responsible GLP-1 prescribing.
As I noted above, the FDA considers salt forms like semaglutide sodium to be different active ingredients. You want a semaglutide base.
Compounded medications use the same active ingredient, but they are not FDA-approved as finished products.
The next step isn’t a purchase. Complete your 5-minute health profile and see if GLP-1 treatment is right for you.
Start hereCompounded semaglutide and Wegovy have the same active ingredient: semaglutide. But they have different regulatory statuses and manufacturing processes. Compounded semaglutide is not FDA-approved as a finished product, but it contains the same active molecule as Wegovy and Ozempic.
Yes, for as long as they come from a licensed 503A pharmacy that follows USP standards and prescribed by a licensed provider after a medical evaluation. But quality varies by pharmacy, which is why choosing the right provider is the most important decision you’ll make.
Compounded semaglutide typically runs $150 to $300/month. Compounded tirzepatide runs $200 to $400/month. Compare that to brand-name self-pay prices of $299 to $449+/month for the lowest options.
This article is for educational purposes only and does not constitute medical advice. Consult a licensed physician regarding any medical condition or treatment.